

CANCER PROFILING AND PATHWAYS: TECHNOLOGIES AND GLOBAL MARKETS



BIO073B
January 2014

Usha Nagavarapu
Project Analyst

ISBN: 1-56965-672-X

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
METHODOLOGY	4
INFORMATION SOURCES	4
ABOUT THE AUTHOR	4
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH ONLINE SERVICES	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
CANCER PROFILING AND PATHWAYS	7
<i>SUMMARY TABLE MARKET FOR CANCER PROFILING TECHNOLOGIES, THROUGH 2018 (\$ MILLIONS)</i>	9
<i>SUMMARY FIGURE MARKET FOR CANCER PROFILING TECHNOLOGIES, 2012-2018 (\$ MILLIONS)</i>	9
CHAPTER 3 OVERVIEW	11
CANCER PROFILING	11
BIOMARKERS	11
GUIDELINES	11
SCREENING TESTS	12
EARLY DETECTION AND DIAGNOSIS OF CANCER	12
PATHWAY PROFILING	13
LINKING CANCER DISEASE THROUGH PATHWAY PROFILING	13
MOLECULAR PROFILING	13
HISTORICAL FACTS	14
MOLECULAR PROFILES	14
ONCOTYPE DX	15
CANCER PROFILING	15
CHALLENGES	16
PRIMARY OBJECTIVES OF THE MINDACT TRIAL	18
Lung Cancer	19
Challenges	19
CLINICAL UTILITY OF MOLECULAR PROFILING	20
CARIS LIFE SCIENCES	21
Head and Neck Cancer Data	22
Pathological Classification	22
MOLECULAR PROFILING APPROACHES	23
<i>TABLE 1 DIFFERENT TOOLS FOR MOLECULAR PROFILING OF CANCER</i>	24
CANCER PROFILING: FUTURE GOALS	25
CHAPTER 4 CURRENT PROFILING TECHNIQUES	27
GENOMICS	27

TOPIC	PAGE NO.
<i>TABLE 2 GENOMICS: TECHNOLOGIES</i>	27
<i>TABLE 3 THE APPLICATIONS MARKET</i>	28
<i>TABLE 4 THE SEGMENT TYPES</i>	28
GENOMIC PROFILING	28
<i>TABLE 5 LIST OF TECHNIQUES/TOOLS FOR GENOMIC PROFILING</i>	30
<i>TABLE 6 GENOMIC REVENUE AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	32
<i>FIGURE 1 GENOMIC REVENUE AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	32
Challenges and Market Trends	32
MICROARRAYS	33
<i>TABLE 7 COMMONLY USED DNA MICROARRAYS</i>	34
Oligonucleotide Microarrays	34
Spotted Microarrays	35
Microarrays Fabrication	35
MICROARRAYS: LIMITATIONS	36
MICROARRAYS AND APPLICATIONS	37
COMPARATIVE GENOMIC HYBRIDIZATION (CGH)	37
Method	38
ARRAY COMPARATIVE GENOME HYBRIDIZATION	38
Applications of Array-CGH	40
CGH AND CANCER	41
Array CGH and Neuroblastoma	41
KEY COMPANIES	42
<i>TABLE 8 SELECTED COMPANIES WITH MICROARRAY TECHNOLOGIES</i>	42
KEY PLAYERS	42
Genomic Profiling - Array Labeling and Genotyping	44
MICROARRAYS TO CLINICAL PROBLEMS	45
SINGLE NUCLEOTIDE POLYMORPHISM (SNP)	45
<i>TABLE 9 KEY COMPANIES</i>	46
MULTI-COLOR FISH	46
Spectral Karyotyping	46
COMPANIES	47
DNA SEQUENCING	47
EMERGING DNA SEQUENCING TECHNOLOGIES	48
Fluorescent in situ Sequencing (FISSEQ)	48
Pyrosequencing	48
Massively Parallel Signature Sequencing (MPSS)	48
Single-Molecule Sequencing	49
Bacterial Artificial Chromosome (BAC)-end Sequencing	49
HIGH-THROUGHPUT SEQUENCING	49
In vitro Clonal Amplification	49
Parallelized Sequencing	50
Sequencing by Ligation	50
Microfluidic Sanger Sequencing	50
OTHER SEQUENCING TECHNOLOGIES	50
APPLICATIONS TO CANCER	51
SEQUENCING TECHNOLOGIES, MARKET AND THEIR APPLICATIONS	52
NEXT-GEN SEQUENCING SERVICES	52

TOPIC	PAGE NO.
<i>TABLE 10 COMPANIES WITH SEQUENCING TECHNOLOGIES</i>	53
Key Companies	53
<i>TABLE 11 NEXT-GEN SEQUENCING COMPANIES</i>	53
THE NEXT NEXT-GENERATION COMPANIES	54
Roche 454 Pyrosequencing	54
Illumina NGS Sequencing	54
Ion Torrent NGS Sequencing	55
Applications of NGS Sequencing	55
LATEST DEVELOPMENTS	55
Complete Genomics	56
Nanopore Sequencing	56
Genia	56
GENOME SEQUENCING	57
PATENTS AND SEQUENCING	58
<i>TABLE 12 SEQUENCING PATENTS AWARDED</i>	58
SUMMARY	59
NEXT-GENERATION SEQUENCING TECHNOLOGIES	59
NEXT-GENERATION SEQUENCING: FUTURE	60
GENOMICS AND CANCER-SOME EXAMPLES	60
<i>TABLE 13 MUTATIONS IDENTIFIED IN CANCER</i>	61
MUTATIONS PREDICTING RESISTANCE TO TARGETED THERAPIES	62
SEQUENCING AND THE CLINIC	62
<i>TABLE 14 CONSORTIUM LISTED RESPONSIBILITIES</i>	63
TRANSCRIPTOMIC PROFILING	65
<i>TABLE 15 TRANSCRIPTOMIC TECHNIQUES</i>	65
MICROARRAY-BASED GENE EXPRESSION PROFILING	66
Serial Analysis of Gene Expression (SAGE)	68
mRNA	68
Data Analysis and Design	69
TILING ARRAYS	70
QRT-PCR	71
APPLICATIONS TO CANCER	71
EMERGING MICROARRAY TECHNOLOGIES	72
MICROARRAY PATENTS	72
FUTURE	73
CHAPTER 5 EPIGENOMIC PROFILING	75
OVERVIEW AND INTRODUCTION TO THE EPIGENETICS LANDSCAPE	75
APPLICATIONS TO CANCER	75
DNA METHYLATION	76
Covalent Histone Modifications	77
Histone Modifications in Cancer	80
MICRORNA	81
MicroRNA Technologies: Impact on Diagnostics and Therapeutics	82
<i>TABLE 16 MIRNA AND SIRNA-A COMPARISON</i>	83
MicroRNA Expression	83
EPIGENETIC CHANGES AND CANCER STEM CELLS	84

TOPIC	PAGE NO.
EPIGENETIC THERAPY OF CANCER	85
TABLE 17 EPIGENETIC DRUGS APPROVED BY THE U.S. FDA	87
TABLE 18 HDAC DRUGS	88
LEADING EPIGENETIC COMPANIES	89
TABLE 19 SELECTED EPIGENETIC COMPANIES	90
EPIGENETICS AND MICRORNA PROFILING-FINDING PATHWAYS TO TREATMENT	91
TABLE 20 CURRENTLY USED MICRORNA TECHNIQUES	92
Human Cancer and Epigenetic Regulation of miRNAs	93
TABLE 21 MICRORNA EXPRESSION IN CANCER	94
TABLE 22 EPI-MIRNAS REGULATING EFFECTORS OF THE EPIGENETIC MACHINERY	95
MICRORNAS AND THERAPEUTIC APPLICATIONS IN CANCER	95
POLYMORPHISMS IN MICRORNAS ASSOCIATED WITH CANCER RISK	97
MICRORNAS AS PROGNOSTIC AND THERAPEUTIC BIOMARKERS	98
microRNA as Therapeutic Targets	98
Computational Methods for Analysis of Cellular Functions and Pathways	99
TABLE 23 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN COLON CANCER	101
ANTI-CANCER DRUGS AND MICRORNA TARGETS	102
TABLE 24 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN PANCREATIC CANCER	103
CASE STUDY: EPIGENETIC SILENCING OF THE INTRONIC MICRORNA MIR-342 IN COLORECTAL CANCER	106
TABLE 25 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN CRC AND NORMAL COLORECTAL TISSUE	107
TABLE 26 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN NORMAL COLON AND EARLY-STAGE COLORECTAL CANCER (STAGES I AND II)	108
TABLE 27 MIRNAS DIFFERENTIALLY EXPRESSED IN EARLY- (I AND II) VS LATE-STAGE (III AND IV) DISEASE	109
TABLE 28 PATHWAYS TARGETED BY CRC MIRNAS	109
DIAGNOSTIC AND THERAPEUTIC MICRORNA STRATEGIES IN CANCER	110
TABLE 29 MICRORNAS AS PROGNOSTIC INDICATORS AND THERAPEUTIC TARGETS: POTENTIAL EFFECT ON BREAST CANCER MANAGEMENT	113
THERAPEUTIC POTENTIAL	114
TABLE 30 MICRORNAS (MIRS) WITH ALTERED EXPRESSION IN OVARIAN CARCINOMA	116
Challenges and Future	118
THERAPEUTIC STRATEGIES	118
Implications for Cancer	120
MICRORNAS IN DISEASE DIAGNOSTICS	120
CIRCULATING MICRORNAS	120
MICRORNA PROFILING METHODS	121
CLINICAL MICRORNA DIAGNOSTICS	121
Nucleotide Polymorphism in Diagnostics	122
MICRORNAS IN THERAPEUTICS	122
TABLE 31 MICRORNA-BASED THERAPEUTICS: DEVELOPMENT STATUS	123
Miravirsen (Santaris Pharma)	124
Regulus Therapeutics	124

TOPIC	PAGE NO.
<i>TABLE 32 SELECTED MICRORNAS IN DEVELOPMENT AND CANCER</i>	125
Mirna Therapeutics	125
miRagen Therapeutics	126
MICRORNA PATENTS AND OUTLOOK	127
Regulus, Alnylam, and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21	127
<i>TABLE 33 MICRORNA PATENTS</i>	128
FUTURE	129
<i>TABLE 34 MICRORNA MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	130
<i>FIGURE 2 MICRORNA MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	130
<i>TABLE 35 SELECTED COMPANIES FOR MIRNA-SPECIFIC TOOLS AND REAGENTS</i>	131
METHYLATION MARKERS	132
DNA METHYLATION, AN EPIGENETIC PROCESS	132
CURRENT METHODS AND PRODUCTS	133
Cancer-Specific Methylation Biomarkers	135
CLINICAL IMPLICATIONS	136
<i>TABLE 36 INTRINSIC CLASSIFICATION OF BREAST CANCER BY GENE EXPRESSION PROFILES AND CELL SURFACE HORMONAL EXPRESSION</i>	137
Clinical Testing	138
Blood-Based Tests	139
FUTURE DIRECTIONS	139
<i>TABLE 37 SELECT EPIGENETIC-BASED DIAGNOSTIC COMPANIES</i>	140
EPIGENETIC DIAGNOSTIC DEVELOPMENT	141
<i>TABLE 38 SELECTED METHYLATION TESTS FOR CANCER</i>	142
EPIGENETIC DRUGS	142
HDAC INHIBITORS	143
Novel HDIs on Trial	144
Celleron	145
Acetylon Pharmaceuticals	145
Syndax	146
<i>TABLE 39 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	147
<i>FIGURE 3 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	147
EPIGENETIC THERAPEUTIC DEVELOPMENT	147
<i>TABLE 40 EPIGENETIC DRUGS FOR CANCER-APPROVED/LATE-STAGE CLINICAL TRIALS</i>	148
Latest Developments	148
September 11, 2013	148
August 27, 2013	149
December 18, 2012	149
September 13, 2012	149
Pracinostat	149
MEI Pharma	150
S*BIO	150
Panobinostat	150
KEY PLAYERS	151
CellCentric	151

TOPIC	PAGE NO.
Epigenomics	151
Constellation Pharmaceuticals	152
Epizyme	152
Abbott	152
Veridex	153
OncoMethylome Sciences	153
<i>TABLE 41 METHYLATION MARKERS IN DEVELOPMENT</i>	154
Quest Diagnostics	154
<i>TABLE 42 SELECTED COMPANIES WITH METHYLATION PRODUCTS</i>	155
Orion Genomics	155
Zymo Research	157
BioChain	157
EpigenDx	157
Rubicon Genomics	158
SeqWright	158
Qiagen	159
<i>TABLE 43 METHYLATION MARKERS/TESTS-PATENTS</i>	160
EXACT Sciences Corporation	160
Activemotif	161
Clinical Implications	163
OncoMethylome Sciences-GST-Pi/APC Methylation Test for Detection of Prostate Cancer	163
MDxHealth	165
Summary	165
CHAPTER 6 PROTEOMICS	167
PROTEOMICS AND PROTEIN PROFILING	167
PROTEOMICS PROTEIN PROFILING APPROACHES	168
TECHNIQUES	170
<i>TABLE 44 BIOMARKER IDENTIFIED USING TWO-DIMENSIONAL ELECTROPHORESIS (2-DE)</i>	170
<i>TABLE 45 BIOMARKER IDENTIFIED USING MASS SPECTROSCOPY (MS)</i>	171
APPLICATIONS OF PROTEOMIC TECHNIQUES IN CANCER RESEARCH	173
TECHNOLOGIES AND LIMITATIONS	174
PROTEOMICS AND INITIATIVES	175
APPLICATIONS TO CANCER	176
PROTEOMICS IN THE TREATMENT OF CANCER	178
CLINICAL APPLICATIONS OF PROTEOMICS	180
Lung Cancer	180
Ovarian Cancer	181
Prostate Cancer	183
Breast Cancer	184
PROTEOMIC APPROACHES IN THERAPEUTIC TARGETS	185
KEY PLAYERS	187
Kreatech Biotechnology	187
Thermo Fisher Scientific	187
GE Healthcare	187
ProteinOne	188

TOPIC	PAGE NO.
Waters	188
PerkinElmer	189
Protneteomix	189
Whatman	189
Arrayit Corporation	190
Qiagen	190
TABLE 46 ANTIBODY ARRAY VENDORS	191
ANALYTICAL SOFTWARE	192
THERAPEUTIC AND DIAGNOSTIC COMPANIES	193
PROTEOMICS-BASED DIAGNOSTIC PRODUCTS	195
Myriad Genetics	195
NextGen Sciences	195
ProFACT Proteomics	195
Proteologics	196
Proteome Factory	196
ProteomTech	197
Pharmaceutical Candidates	197
Quattromed	198
Sense Proteomic Limited	198
SomaLogic	198
Structural Bioinformatics (SBI)	198
WITA Proteomics	199
Zyomyx	199
PROTEOMIC RESEARCH CENTERS	200
Stanford University: Molecular Therapeutics Program	200
Vanderbilt University-Mass Spectrometry Research Center (MSRC)	200
CLINICAL TRIAL USING PROTEOMICS TECHNOLOGIES FOR PERSONALIZED MEDICINE	202
PROTEOMICS AND MEDICINE	203
PROTEOMICS MARKET	203
TABLE 47 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, THROUGH 2018 (\$ MILLIONS)	203
FIGURE 4 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, 2012-2018 (\$ MILLIONS)	204
Applied Proteomics	204
CHAPTER 7 GLYCOMICS	207
WHAT IS GLYCOMICS?	207
TECHNIQUES	207
ANALYTICAL HIGH-THROUGHPUT TECHNOLOGIES	209
EMERGENCE OF GLYCOARRAYS	209
GLYCOINFORMATICS	210
BIOMEDICAL APPLICATIONS	210
GLYCOMICS'S RELATIONSHIP WITH OTHER "OMICS" TECHNOLOGIES	211
GLYCOMICS FOR BIOMARKER DISCOVERY	212
TABLE 48 THE SEVEN TUMOR GLYCOME LABORATORIES	212
CANCER AND GLYCOMICS	213
Glycomics-Biomarkers for Ovarian Cancer	213

TOPIC	PAGE NO.
<i>TABLE 49 CLINICAL TRIALS AND GLYCOMICS</i>	214
GLYCOMICS AND PATENTS	215
Carbohydrate Encapsulated Nanoparticles	215
Glycosylated Specificity Exchangers (Tripep)	215
Glycosylated Specificity Exchangers (Tripep)	215
Tripep AB/ChronTech Pharma AB	215
<i>TABLE 50 GLYCOMICS PATENTS</i>	216
Serum Marker for Measuring Liver Fibrosis	216
Recent Advances	217
CHAPTER 8 METABOLOMICS	219
WHAT IS METABOLOMICS?	219
METABOLOME	219
Techniques	220
Detection Methods	221
METABOLOMICS AND DRUG DISCOVERY	222
BIOMARKER IDENTIFICATION	222
CHAPTER 9 BIOINFORMATICS, DATABASES AND PATHWAY ANALYSIS	225
MICROARRAY DATABASE	225
<i>TABLE 51 SOME OF THE MOST KNOWN PUBLIC, CURATED MICROARRAY DATABASES</i>	226
CHAPTER 10 CANCER PROFILING AND CLINICAL DEVELOPMENT	231
NODALITY	231
ROSETTA CANCER TESTING SERVICES	232
IRIS BIOTECHNOLOGIES	232
IN BREAST CANCER-THREE PERSPECTIVES ILLUSTRATING CURRENT CHALLENGES IN PERSONALIZED MEDICINE	233
BIOMARKERS	235
DIAGNOSTIC TESTS IN DEVELOPMENT	235
<i>TABLE 52 DIAGNOSTIC TESTS IN DEVELOPMENT</i>	235
APPROVED TESTS	236
Affymetrix	236
Agendia	236
<i>TABLE 53 APPROVED DIAGNOSTIC TESTS</i>	237
GENOMIC ASSAYS	238
<i>TABLE 54 CURRENT LEADERS IN THE GENOMIC MARKET</i>	239
GENOMIC HEALTH BUSINESS PROGRESS	239
<i>TABLE 55 ONCOTYPE DX SALES AND FORECAST, 2010-2012 (\$ MILLIONS)</i>	239
MammaPrint Assay	239
CANCER AND BIOMARKERS	240
<i>TABLE 56 KEY PREDICTIVE BIOMARKERS FOR TRASTUZUMAB THERAPY</i>	242
<i>TABLE 57 PREDICTIVE BIOMARKERS FOR EGFR TKI THERAPIES IN LUNG CANCER</i>	244
FUTURE DIRECTIONS	248
<i>TABLE 58 PREDICTIVE BIOMARKERS FOR ANTI-EGFR ANTIBODY THERAPIES IN COLORECTAL CANCER</i>	249

TOPIC	PAGE NO.
CHAPTER 11 MARKET	252
GLOBAL DNA DIAGNOSTICS MARKET	252
TABLE 59 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, THROUGH 2018 (\$ MILLIONS)	252
FIGURE 5 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, 2012-2018 (\$ MILLIONS)	252
THE CANCER DIAGNOSTICS MARKET	253
CANCER DIAGNOSTIC TESTS	253
THE CANCER/TUMOR PROFILING MARKET	253
TABLE 60 CANCER PROFILING MARKET: SEGMENT TYPES	254
TABLE 61 GLOBAL CANCER PROFILING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	254
TABLE 62 CANCER PROFILING MARKET: APPLICATIONS	255
TABLE 63 CANCER PROFILING MARKET: TECHNOLOGIES	255
PERSONALIZED MEDICINE	255
CANCER BIOMARKER TESTING MARKET	256
TABLE 64 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	257
FIGURE 6 GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	257
TABLE 65 THE KEY PLAYERS	258
TABLE 66 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	258
FIGURE 7 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	258
CANCER BIOMARKER TESTS	259
CANCER DISEASE MANAGEMENT	259
GENOMICS MARKET	260
Trends	261
TABLE 67 GENOMICS MARKET REVENUE AND FORECAST, THROUGH 2018 (\$ MILLIONS)	261
FIGURE 8 GENOMICS MARKET REVENUE AND FORECAST, 2012-2018 (\$ MILLIONS)	261
SNP GENOTYPING AND ANALYSIS MARKET	262
TABLE 68 SNP GENOTYPING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	262
FIGURE 9 SNP GENOTYPING MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	263
MICROARRAY MARKET	263
TABLE 69 GLOBAL BIOCHIPS MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	264
FIGURE 10 GLOBAL BIOCHIPS MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	264
TABLE 70 GLOBAL BIOCHIPS MARKET SHARE (%)	265
TABLE 71 MICROARRAY MARKETS	266
Key Microarray Companies	266
Microarray Use	267
TABLE 72 MICROARRAYS: MODALITIES	267
Global Microarray Market	268
TABLE 73 GLOBAL MICROARRAY MARKET FORECAST, THROUGH 2018 (\$ MILLIONS)	268
FIGURE 11 GLOBAL MICROARRAY MARKET FORECAST 2012-2018 (\$ MILLIONS)	268
TABLE 74 MICROARRAY MARKET SHARE, 2012 (%)	269
BIOCHIP/LAB-ON-A-CHIP (LOAC) MARKET	269
TABLE 75 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, THROUGH 2018 (\$ MILLIONS)	270

TOPIC	PAGE NO.
<i>FIGURE 12 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, 2010-2018 (\$ MILLIONS)</i>	270
DIAGNOSTIC MICROARRAYS	270
<i>TABLE 76 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	271
<i>FIGURE 13 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	271
<i>TABLE 77 SOME COMMERCIALY AVAILABLE CANCER DIAGNOSTIC DEVICES BASED ON MICROARRAY TECHNOLOGY</i>	272
In Situ Hybridization Diagnostic Arrays	272
<i>TABLE 78 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	272
<i>FIGURE 14 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	272
Microarray Market Growth	273
<i>TABLE 79 MICROARRAY TECHNOLOGIES: KEY COMPANIES AND PRODUCTS</i>	274
DNA Microarrays	275
<i>FIGURE 15 GLOBAL MICROARRAY MARKET FORECAST, 2012-2018 (\$ MILLIONS)</i>	276
MARKET DYNAMICS	276
KEY PLAYERS	277
Affymetrix	277
Recent Developments	277
<i>TABLE 81 AFFYMETRIX UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (THOUSANDS)</i>	278
Agilent Technologies	278
<i>TABLE 82 AGILENT TECHNOLOGIES NET REVENUE, 2012 (\$ MILLIONS)</i>	278
Product Sales	279
<i>TABLE 83 GENE EXPRESSION PRODUCTS: MARKET SHARE COMPANIES, 2012 (%)</i>	279
Strategic Alliances and Acquisitions	280
Historical Trends and Future	281
<i>TABLE 84 MICROARRAY PRODUCTS</i>	281
Illumina	281
Pacific Biosciences	282
Arrayit Corporation	282
<i>TABLE 85 ARRAYIT PATENTS</i>	283
Arrayit Products	283
<i>TABLE 86 ARRAYIT CORPORATION REVENUE, BY FISCAL QUARTER, 2011-2013 (\$)</i>	284
Arrayit's Future	285
Roche	285
PerkinElmer	286
Boreal Genomics	286
DNA SEQUENCING MARKET	286
First-Generation DNA Sequencing	286
NEXT-GENERATION SEQUENCING SYSTEMS	287
A NEW GENERATION OF DNA SEQUENCING	287
DNA SEQUENCING AND PERSONALIZED MEDICINE	288
<i>TABLE 87 SEQUENCING-SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	289
<i>FIGURE 16 SEQUENCING-SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	289
<i>TABLE 88 THE NEXT-GENERATION SEQUENCING (NGS) MARKET: PLATFORMS</i>	290
HISTORY	290

TOPIC	PAGE NO.
<i>TABLE 89 CLINICAL NEXT-GENERATION SEQUENCING INDUSTRY ACQUISITIONS, 2011-2013</i>	292
NEXT-GENERATION SEQUENCING INSTRUMENT INDUSTRY	293
<i>TABLE 90 NEXT-GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%)</i>	294
<i>TABLE 91 NEXT-GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%)</i>	295
NEXT-GENERATION SEQUENCING TARGET ENRICHMENT INDUSTRY	296
<i>TABLE 92 NEXT-GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY COMPANY PLATFORM METHOD</i>	296
<i>TABLE 93 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS</i>	298
Developments	298
Roche	299
Illumina	299
<i>TABLE 94 ILLUMINA REVENUE AND FORECAST, 2012-2015 (\$ MILLIONS)</i>	300
<i>TABLE 95 ILLUMINA NEW DEVELOPMENTS</i>	300
<i>TABLE 96 ILLUMINA PRODUCT AND SERVICE REVENUE AND FORECAST, 2012-2015 (\$ MILLIONS)</i>	301
<i>TABLE 97 ILLUMINA-REVENUE, 2008-2010 (\$ MILLIONS)</i>	302
<i>FIGURE 17 ILLUMINA-REVENUE, 2008-2010 (\$ MILLIONS)</i>	302
<i>TABLE 98 SELECTED COMPANIES AND SEQUENCING PRODUCTS</i>	303
MARKET SHARE	303
Oxford Nanopore	304
Life Technologies	304
<i>TABLE 99 LIFE TECHNOLOGIES REVENUES, 2008-2010 (\$ MILLIONS)</i>	305
<i>FIGURE 18 LIFE TECHNOLOGIES REVENUES, 2008-2010 (\$ MILLIONS)</i>	305
PCR MARKET	307
<i>TABLE 100 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	307
<i>FIGURE 19 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	307
<i>TABLE 101 KEY PCR COMPANIES</i>	308
<i>TABLE 102 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	309
<i>FIGURE 20 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	309
REAL-TIME PCR MARKET	309
<i>TABLE 103 REAL-TIME (QRT-PCR) PCR SELECTED COMPANIES</i>	310
<i>TABLE 104 REAL-TIME (QRT-PCR) MARKET, THROUGH 2018 (\$ MILLIONS)</i>	311
<i>FIGURE 21 REAL-TIME (QRT-PCR) MARKET, 2012-2018 (\$ MILLIONS)</i>	311
EPIGENETICS AND MARKET	312
<i>TABLE 105 GLOBAL EPIGENETIC MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	313
<i>FIGURE 22 GLOBAL EPIGENETIC MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	314
<i>TABLE 106 EPIGENETIC MARKET: KEY PLAYERS</i>	314
<i>TABLE 107 EPIGENETICS ARRAYS AND SELECTED CANCER PROFILING COMPANIES</i>	315
EPIGENETIC THERAPEUTICS	316
<i>TABLE 108 DRUGS APPROVED BY THE FDA AND COMMERCIALY AVAILABLE</i>	316
FUTURE: EPIGENETIC THERAPIES	317

TOPIC	PAGE NO.
<i>TABLE 109 EPIGENETICS AND SELECTED COMPANIES</i>	318
EPIGENETICS AND DIAGNOSTIC TESTS	319
<i>TABLE 110 EPIGENETIC DIAGNOSTIC TESTS</i>	319
MIRNA MARKET	319
<i>TABLE 111 TOTAL MIRNA MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	320
<i>FIGURE 23 TOTAL MIRNA MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	321
<i>TABLE 112 TOTAL MIRNA MARKET INCLUDING SALES, 2008 (%)</i>	322
EPIGENETICS AND CANCER MARKET AND FUTURE GROWTH	322
<i>TABLE 113 SELECTED COMPANIES WITH METHYLATION PRODUCTS</i>	323
CURRENT USE OF PROTEOMICS IN THE PHARMA INDUSTRY	323
<i>TABLE 114 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	323
<i>FIGURE 24 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, 2012-2018 (\$ MILLIONS)</i>	323
<i>TABLE 115 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	324
<i>FIGURE 25 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	324
PROTEIN MICROARRAYS AND TRENDS	325
THE METABOLOMICS MARKET	326
FUTURE	328
CONCLUSION	329
<i>TABLE 116 SELECTED COMPANIES OFFERING, DEVELOPING OR PARTNERING TO DEVELOP COMPANION DIAGNOSTICS</i>	329
CHAPTER 12 COMPANY PROFILES	332
KEY PLAYERS	332
ABBOTT LABORATORIES	332
AFFYMETRIX	332
AGENDIA	333
AGILENT TECHNOLOGIES	334
ARRAYIT	334
ASTRAZENECA PLC.	335
ASURAGEN, INC.	335
BOREAL GENOMICS	336
CARIS LIFE SCIENCES	336
CLARINET	336
DAKO	337
EISAI INC. (HEADQUARTERS)	337
ENDOTIS PHARMA	338
EPPENDORF BIOCHIP SYSTEMS	338
EXIQON, INC	338
GENOMIC HEALTH	339
GLAXOSMITHKLINE	339
GLYCOMINDS LIMITED	339
GP BIOSCIENCES	340
IKARYOS DIAGNOSTICS	340
ILLUMINA	341

TOPIC	PAGE NO.
LIFE TECHNOLOGIES	341
LIPOMICS TECHNOLOGIES	341
MERCK	342
METABOLON	342
MIRAGEN THERAPEUTICS	342
MIRNA THERAPEUTICS INC.	343
OXFORD GENE TECHNOLOGY	343
Oxford Nanopore Technologies	343
PACIFIC BIOSCIENCES	344
PERKINELMER	344
PFIZER	345
PROTEOME SCIENCES	345
RAYBIOTECH	345
REGULUS THERAPEUTICS	346
ROCHE	346
RUBICON GENOMICS	346
<i>TABLE 117 MICROARRAY COMPANIES</i>	347
CHAPTER 13 CANCER PROFILING: PATENT LANDSCAPE AND LATEST DEVELOPMENTS	350
<i>TABLE 118 PATENT APPLICATIONS IN MICROARRAYS</i>	351
MIRNA THERAPEUTICS	354
TROVAGENE	355
<i>TABLE 119 COMPANIES DEVELOPING MIRNA-RELATED TECHNOLOGIES</i>	356
COLUMBIA UNIVERSITY SUES ILLUMINA OVER DNA SEQUENCING PATENTS	357
MAJOR CANCER GENOTYPING STUDY LOGS 5,000TH TUMOR PROFILE	358
Developing a Cancer-Specific Microarray	359
Oxford Nanopore Announces \$64 Million Fundraising	359
Silicon Peptide Chips Could Transform Diagnostics	359
Agilent Technologies Introduces HaloPlex Exome Kits and SureCall Software	360
PROTEOME SCIENCES	361
CONCLUSIONS	362
CHAPTER 14 REFERENCES	364
CHAPTER 15 CITED REFERENCES	368
CITED REFERENCES	368

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE MARKET FOR CANCER PROFILING TECHNOLOGIES, THROUGH 2018 (\$ MILLIONS)	9
TABLE 1 DIFFERENT TOOLS FOR MOLECULAR PROFILING OF CANCER	24
TABLE 2 GENOMICS: TECHNOLOGIES	27
TABLE 3 THE APPLICATIONS MARKET	28
TABLE 4 THE SEGMENT TYPES	28
TABLE 5 LIST OF TECHNIQUES/TOOLS FOR GENOMIC PROFILING	30
TABLE 6 GENOMIC REVENUE AND FORECAST, THROUGH 2018 (\$ MILLIONS)	32
TABLE 7 COMMONLY USED DNA MICROARRAYS	34
TABLE 8 SELECTED COMPANIES WITH MICROARRAY TECHNOLOGIES	42
TABLE 9 KEY COMPANIES	46
TABLE 10 COMPANIES WITH SEQUENCING TECHNOLOGIES	53
TABLE 11 NEXT-GEN SEQUENCING COMPANIES	53
TABLE 12 SEQUENCING PATENTS AWARDED	58
TABLE 13 MUTATIONS IDENTIFIED IN CANCER	61
TABLE 14 CONSORTIUM LISTED RESPONSIBILITIES	63
TABLE 15 TRANSCRIPTOMIC TECHNIQUES	65
TABLE 16 MIRNA AND SIRNA-A COMPARISON	83
TABLE 17 EPIGENETIC DRUGS APPROVED BY THE U.S. FDA	87
TABLE 18 HDAC DRUGS	88
TABLE 19 SELECTED EPIGENETIC COMPANIES	90
TABLE 20 CURRENTLY USED MICRORNA TECHNIQUES	92
TABLE 21 MICRORNA EXPRESSION IN CANCER	94
TABLE 22 EPI-MIRNAS REGULATING EFFECTORS OF THE EPIGENETIC MACHINERY	95
TABLE 23 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN COLON CANCER	101
TABLE 24 LIST OF PREDICTED TARGETS THAT ARE KNOWN GENES AFFECTED IN PANCREATIC CANCER	103
TABLE 25 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN CRC AND NORMAL COLORECTAL TISSUE	107
TABLE 26 MIRNAS DIFFERENTIALLY EXPRESSED BETWEEN NORMAL COLON AND EARLY-STAGE COLORECTAL CANCER (STAGES I AND II)	108
TABLE 27 MIRNAS DIFFERENTIALLY EXPRESSED IN EARLY- (I AND II) VS LATE-STAGE (III AND IV) DISEASE	109
TABLE 28 PATHWAYS TARGETED BY CRC MIRNAS	109
TABLE 29 MICRORNAS AS PROGNOSTIC INDICATORS AND THERAPEUTIC TARGETS: POTENTIAL EFFECT ON BREAST CANCER MANAGEMENT	113
TABLE 30 MICRORNAS (MIRS) WITH ALTERED EXPRESSION IN OVARIAN CARCINOMA	116
TABLE 31 MICRORNA-BASED THERAPEUTICS: DEVELOPMENT STATUS	123
TABLE 32 SELECTED MICRORNAS IN DEVELOPMENT AND CANCER	125
TABLE 33 MICRORNA PATENTS	128
TABLE 34 MICRORNA MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	130
TABLE 35 SELECTED COMPANIES FOR MIRNA-SPECIFIC TOOLS AND REAGENTS	131
TABLE 36 INTRINSIC CLASSIFICATION OF BREAST CANCER BY GENE EXPRESSION PROFILES AND CELL SURFACE HORMONAL EXPRESSION	137
TABLE 37 SELECT EPIGENETIC-BASED DIAGNOSTIC COMPANIES	140
TABLE 38 SELECTED METHYLATION TESTS FOR CANCER	142

TABLE HEADING	PAGE NO.
TABLE 39 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	147
TABLE 40 EPIGENETIC DRUGS FOR CANCER-APPROVED/LATE-STAGE CLINICAL TRIALS	148
TABLE 41 METHYLATION MARKERS IN DEVELOPMENT	154
TABLE 42 SELECTED COMPANIES WITH METHYLATION PRODUCTS	155
TABLE 43 METHYLATION MARKERS/TESTS-PATENTS	160
TABLE 44 BIOMARKER IDENTIFIED USING TWO-DIMENSIONAL ELECTROPHORESIS (2-DE)	170
TABLE 45 BIOMARKER IDENTIFIED USING MASS SPECTROSCOPY (MS)	171
TABLE 46 ANTIBODY ARRAY VENDORS	191
TABLE 47 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, THROUGH 2018 (\$ MILLIONS)	203
TABLE 48 THE SEVEN TUMOR GLYCOME LABORATORIES	212
TABLE 49 CLINICAL TRIALS AND GLYCOMICS	214
TABLE 50 GLYCOMICS PATENTS	216
TABLE 51 SOME OF THE MOST KNOWN PUBLIC, CURATED MICROARRAY DATABASES	226
TABLE 52 DIAGNOSTIC TESTS IN DEVELOPMENT	235
TABLE 53 APPROVED DIAGNOSTIC TESTS	237
TABLE 54 CURRENT LEADERS IN THE GENOMIC MARKET	239
TABLE 55 ONCOTYPE DX SALES AND FORECAST, 2010-2012 (\$ MILLIONS)	239
TABLE 56 KEY PREDICTIVE BIOMARKERS FOR TRASTUZUMAB THERAPY	242
TABLE 57 PREDICTIVE BIOMARKERS FOR EGFR TKI THERAPIES IN LUNG CANCER	244
TABLE 58 PREDICTIVE BIOMARKERS FOR ANTI-EGFR ANTIBODY THERAPIES IN COLORECTAL CANCER	249
TABLE 59 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, THROUGH 2018 (\$ MILLIONS)	252
TABLE 60 CANCER PROFILING MARKET: SEGMENT TYPES	254
TABLE 61 GLOBAL CANCER PROFILING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	254
TABLE 62 CANCER PROFILING MARKET: APPLICATIONS	255
TABLE 63 CANCER PROFILING MARKET: TECHNOLOGIES	255
TABLE 64 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	257
TABLE 65 THE KEY PLAYERS	258
TABLE 66 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	258
TABLE 67 GENOMICS MARKET REVENUE AND FORECAST, THROUGH 2018 (\$ MILLIONS)	261
TABLE 68 SNP GENOTYPING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	262
TABLE 69 GLOBAL BIOCHIPS MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	264
TABLE 70 GLOBAL BIOCHIPS MARKET SHARE (%)	265
TABLE 71 MICROARRAY MARKETS	266
TABLE 72 MICROARRAYS: MODALITIES	267
TABLE 73 GLOBAL MICROARRAY MARKET FORECAST, THROUGH 2018 (\$ MILLIONS)	268
TABLE 74 MICROARRAY MARKET SHARE, 2012 (%)	269
TABLE 75 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, THROUGH 2018 (\$ MILLIONS)	270
TABLE 76 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	271

TABLE HEADING	PAGE NO.
TABLE 77 SOME COMMERCIALY AVAILABLE CANCER DIAGNOSTIC DEVICES BASED ON MICROARRAY TECHNOLOGY	272
TABLE 78 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	272
TABLE 79 MICROARRAY TECHNOLOGIES: KEY COMPANIES AND PRODUCTS	274
TABLE 81 AFFYMETRIX UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (THOUSANDS)	278
TABLE 82 AGILENT TECHNOLOGIES NET REVENUE, 2012 (\$ MILLIONS)	278
TABLE 83 GENE EXPRESSION PRODUCTS: MARKET SHARE COMPANIES, 2012 (%)	279
TABLE 84 MICROARRAY PRODUCTS	281
TABLE 85 ARRAYIT PATENTS	283
TABLE 86 ARRAYIT CORPORATION REVENUE, BY FISCAL QUARTER, 2011-2013 (\$)	284
TABLE 87 SEQUENCING-SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	289
TABLE 88 THE NEXT-GENERATION SEQUENCING (NGS) MARKET: PLATFORMS	290
TABLE 89 CLINICAL NEXT-GENERATION SEQUENCING INDUSTRY ACQUISITIONS, 2011-2013	292
TABLE 90 NEXT-GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%)	294
TABLE 91 NEXT-GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013 (UNITS/%)	295
TABLE 92 NEXT-GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY COMPANY PLATFORM METHOD	296
TABLE 93 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS	298
TABLE 94 ILLUMINA REVENUE AND FORECAST, 2012-2015 (\$ MILLIONS)	300
TABLE 95 ILLUMINA NEW DEVELOPMENTS	300
TABLE 96 ILLUMINA PRODUCT AND SERVICE REVENUE AND FORECAST, 2012-2015 (\$ MILLIONS)	301
TABLE 97 ILLUMINA-REVENUE, 2008-2010 (\$ MILLIONS)	302
TABLE 98 SELECTED COMPANIES AND SEQUENCING PRODUCTS	303
TABLE 99 LIFE TECHNOLOGIES REVENUES, 2008-2010 (\$ MILLIONS)	305
TABLE 100 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	307
TABLE 101 KEY PCR COMPANIES	308
TABLE 102 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	309
TABLE 103 REAL-TIME (QRT-PCR) PCR SELECTED COMPANIES	310
TABLE 104 REAL-TIME (QRT-PCR) MARKET, THROUGH 2018 (\$ MILLIONS)	311
TABLE 105 GLOBAL EPIGENETIC MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	313
TABLE 106 EPIGENETIC MARKET: KEY PLAYERS	314
TABLE 107 EPIGENETICS ARRAYS AND SELECTED CANCER PROFILING COMPANIES	315
TABLE 108 DRUGS APPROVED BY THE FDA AND COMMERCIALY AVAILABLE	316
TABLE 109 EPIGENETICS AND SELECTED COMPANIES	318
TABLE 110 EPIGENETIC DIAGNOSTIC TESTS	319
TABLE 111 TOTAL MIRNA MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	320
TABLE 112 TOTAL MIRNA MARKET INCLUDING SALES, 2008 (%)	322
TABLE 113 SELECTED COMPANIES WITH METHYLATION PRODUCTS	323
TABLE 114 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, THROUGH 2018 (\$ MILLIONS)	323

TABLE HEADING	PAGE NO.
TABLE 115 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	324
TABLE 116 SELECTED COMPANIES OFFERING, DEVELOPING OR PARTNERING TO DEVELOP COMPANION DIAGNOSTICS	329
TABLE 117 MICROARRAY COMPANIES	347
TABLE 118 PATENT APPLICATIONS IN MICROARRAYS	351
TABLE 119 COMPANIES DEVELOPING MIRNA-RELATED TECHNOLOGIES	356

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE MARKET FOR CANCER PROFILING TECHNOLOGIES, 2012-2018 (\$ MILLIONS)	9
FIGURE 1 GENOMIC REVENUE AND FORECAST, 2012-2018 (\$ MILLIONS)	32
FIGURE 2 MICRORNA MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	130
FIGURE 3 TOTAL EPIGENETIC PROFILING MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	147
FIGURE 4 PROTEOMICS MARKET AND FORECAST FOR CANCER PROFILING, 2012-2018 (\$ MILLIONS)	204
FIGURE 5 GLOBAL DNA DIAGNOSTICS MARKET FORECAST, 2012-2018 (\$ MILLIONS)	252
FIGURE 6 GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	257
FIGURE 7 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	258
FIGURE 8 GENOMICS MARKET REVENUE AND FORECAST, 2012-2018 (\$ MILLIONS)	261
FIGURE 9 SNP GENOTYPING MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	263
FIGURE 10 GLOBAL BIOCHIPS MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	264
FIGURE 11 GLOBAL MICROARRAY MARKET FORECAST 2012-2018 (\$ MILLIONS)	268
FIGURE 12 GLOBAL LAB-ON-A-CHIP MARKET FORECAST, 2010-2018 (\$ MILLIONS)	270
FIGURE 13 DIAGNOSTIC MICROARRAY MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	271
FIGURE 14 IN SITU HYBRIDIZATION DIAGNOSTIC ARRAYS: MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	272
FIGURE 15 GLOBAL MICROARRAY MARKET FORECAST, 2012-2018 (\$ MILLIONS)	276
FIGURE 16 SEQUENCING-SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	289
FIGURE 17 ILLUMINA-REVENUE, 2008-2010 (\$ MILLIONS)	302
FIGURE 18 LIFE TECHNOLOGIES REVENUES, 2008-2010 (\$ MILLIONS)	305
FIGURE 19 GLOBAL POLYMERASE CHAIN REACTION MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	307
FIGURE 20 GLOBAL POLYMERASE CHAIN REACTION-BASED DIAGNOSTIC ASSAYS MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	309
FIGURE 21 REAL-TIME (QRT-PCR) MARKET, 2012-2018 (\$ MILLIONS)	311
FIGURE 22 GLOBAL EPIGENETIC MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	314
FIGURE 23 TOTAL MIRNA MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	321
FIGURE 24 GLOBAL MARKET FOR PROTEOMICS-SALES FORECAST, 2012-2018 (\$ MILLIONS)	323
FIGURE 25 PROTEIN-BASED MICROARRAYS MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	324